While genomic data suggest an oncogenic role for CDK4/6 in EC, a Phase-II trial combining letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer reported a superior combination treatment efficacy (Konstantinopoulos et al., 2023). This evidence concerns the gene CDK4 and endometrial cancer.